KR20220020633A - Injectable composition for promoting hair growth or preventing hair loss - Google Patents

Abstract

The present invention relates to an injectable composition for preventing hair loss or promoting hair growth, containing sodium (meta)arsenite as an active ingredient. The present invention has the advantages of having no side effects while exhibiting excellent hair loss prevention and hair growth promotion effects. In order to achieve the above object, the present invention provides the injectable composition for preventing hair loss or promoting hair growth, containing sodium (meta)arsenite as the active ingredient.

Description

Injectable composition for preventing hair loss or promoting hair growth {Injectable composition for promoting hair growth or preventing hair loss}

The present invention relates to an injection composition that exhibits the effect of preventing hair loss and promoting hair growth.

The causes of hair loss include the theory that excessive male hormone action, excessive sebum secretion, poor blood circulation, peroxide, and decreased scalp function caused by bacteria, genetic factors, aging, and stress are being discussed. In addition, the population with hair loss is gradually increasing due to environmental pollution, westernized eating habits such as instant food, frequent perms and dyeing, etc. along with an increase in social stress. The hair cycle consists of the anagen phase when hair grows, the catagen phase when growth ends and the hair bulb shrinks, the talogen phase when the dermal papilla stops and the hair stays on the scalp, and the dermal papilla is active It can be divided into the developmental period, which is the period when old hair is depilated by starting or generating new hair.

Anagen Stage (2-7 years) is the period of hair growth, and it is divided into the hair generation stage, when the hair goes out from the hair follicle to the follicle, and the stage where hard keratin is made in the hair follicle. Hair continues to grow on its own until the catagen stage.

Catagen Stage (2~3 weeks) is the period when the growth phase ends and the metabolic process slows down while maintaining the shape of the hair. In this stage, keratin is not produced. The catagen stage accounts for 1% of all hair. At this time, the hair bulb is contracted and divided into dermal papilla, surrounded by hair follicles and ascending upwards, and cell division is in a stationary state.

In the telogen stage (3 months), the dermal papilla atrophy, the hair follicles gradually shrink, and the hair roots are pushed upwards and fall out. As the period of hair loss, the lifespan until the next growth phase begins is 3 to 4 months.

A normal person has a lot of hair in the growth phase, whereas a person with alopecia has a lot of hair in the telogen phase, which causes visible hair loss. As hair loss progresses, the growth period becomes shorter and the hair becomes smaller and smaller.

Therefore, for the treatment of hair loss, it is important to allow the hair follicles in the resting state to quickly go to the growth phase and to extend the shortened growth phase.

Androgenetic alopecia is a phenomenon that is caused by a male hormone called testosterone. When testosterone is converted into a more powerful hormone, dihydrotestosterone (DHT) by an enzyme called α-reductase, this Hormones act on the hair follicles to induce hair follicles from the growth phase to the degeneration phase, causing hair loss. Therefore, in order to treat androgenetic alopecia, a method of inhibiting the production of DHT by 5-alpha-reductase is mainly used.

Gynecomastia is mainly caused by a decrease in the amount of estrogen after menopause. The main treatment for female pattern alopecia is minoxidil. Trichosaccharides or estrogen are used.

Alopecia areata is caused by autoimmune diseases, mental stress, or genetic predisposition. Alopecia areata has a fundamentally different cause from androgenetic alopecia, and the treatment is different, so a method of treating adrenocortical hormones, applying minoxidil to the affected area, or artificially stimulating the affected area is used.

However, in the case of minoxidil, tricosaccharide, etc., which have been known to prevent hair loss and have effects on hair growth and hair growth, lack of clear efficacy and side effects such as human safety are emerging, so safety and efficacy are secured There is an urgent need to develop a suitable composition.

1. Republic of Korea Patent Registration No. 10-0839704 2. Republic of Korea Patent Registration No. 10-1070992 3. Korean Patent Registration No. 10-1205209

As a result of continuous research on the effects of preventing hair loss and promoting hair growth, the present inventors have completed the present invention by confirming that the effects of preventing hair loss and promoting hair growth by metaarsenite salt are excellent and there are no side effects. Accordingly, it is an object of the present invention to provide an injection composition comprising a metaarsenite salt having an effect of preventing hair loss or promoting hair growth as an active ingredient.

In order to achieve the above object, the present invention provides an injection composition for preventing hair loss and promoting hair growth comprising metaarsenite salt as an active ingredient.

In the injection composition for preventing hair loss and promoting hair growth according to the present invention, the metaarsenite salt is preferably an alkali metal salt or an alkaline earth metal salt, more preferably a potassium salt or a sodium salt.

The injection composition according to the present invention has the advantage of having no side effects while showing excellent hair loss prevention and hair growth promoting effects.

1 is a view showing the growth images of hair follicles treated with sodium metaarsenite at 0.03 and 0.3 μg/ml and cultured for 0, 5, 7, 9, 12 days.
Figure 2 shows a photograph taken to confirm the hair growth promoting effect when treated in C57BL/6 mice.

The present invention relates to an injection composition for preventing hair loss and promoting hair growth comprising a meta arsenite salt as an active ingredient, wherein the meta arsenite salt is preferably an alkali metal salt or an alkaline earth metal salt, more preferably a potassium salt or sodium salt.

In the present invention, the term "injection" refers to injecting a drug solution intradermally, subcutaneously, intramuscularly, intravenously or into an artery using a syringe. Specifically, the injection may be a subcutaneous injection due to the characteristic that the pharmaceutical composition of the present invention exhibits the efficacy of preventing hair loss or promoting hair growth, but is not limited thereto. The syringe can be used without limitation as long as it is a syringe used for subcutaneously administering the pharmaceutical composition of the present invention as well as a general syringe capable of administering a drug through a needle.

In the present invention, the pharmaceutical composition for injection may be in the form of a liquid or dry powder. The dry powder for injection may be administered to a subject by reconstitution with any one or more selected from water for injection, physiological saline, glucose solution, and amino acid solution when administered to a patient.

In addition, in the present invention, the active ingredient is an excipient such as water for injection for making an injection composition excluding metaarsenite salt, as long as it is widely known in the art to which the present invention belongs, it can be used without particular limitation.

Hereinafter, the invention according to the present invention will be described in detail through Examples, and the scope of rights is not limited by the Examples. However, it is clear that the same effect can be predicted in other salts, and the test dose and formulation are also used as examples to measure the effect, so there is no need to limit the interpretation of the scope of rights.

< Example 1>

Testing Institution : Bioalternatives, Inc. (France)

Test purpose : In this study, hair follicles were cultured using a human ex vivo model, and sodium metaarsenite containing metaarsenite ions was treated at an optimal concentration for hair follicle cell proliferation, thereby affecting hair growth and survival. was verified. In this study, the co-culture model for culturing hair follicle cells was conducted by establishing the most stable culture conditions for hair growth and survival as the environmental conditions most similar to human hair follicle cells.

Test method and results

Hair follicle cell model and culture conditions

A 37-year-old male (n°E1758) underwent face lift and a small amount of hair follicle cells was obtained from the skin fragment.

Hair follicle cells were cultured in William's medium E containing penicillin 50U/ml, streptomycin 50㎍/ml, L-glutamine 2mM, insulin 10㎍/ml, hydrocortisone 4ng/ml at 37°C in the presence of 5% carbon dioxide. .

sodium of meta arsenite condition

Sodium metaarsenite used in the test (CAS Number:7784-45-5, Batch n° SLBW7984, Ref. S7400 Sigma, Purity:100%, AD180303-1(R00838) was purchased in powder form from Sigma and stored at room temperature. It was used, and it was prepared at 1 mg/ml in William's medium E, which is a culture medium.

For the hair follicle proliferation experiment, sodium metaarsenite was used at concentrations of 0.03 μg/ml and 0.3 μg/ml, respectively.

Image analysis for hair growth experiments

NIKON DS-Fi1 camera and image J software were used as equipment to check the image, and the image recorded in the report provided by Bioalternatives, Inc. was checked.

Hair growth experiment using hair follicle cells

Hair follicles were obtained in a 24-well plate (1 follicle/well) containing a culture medium.

The length of the hair follicle from day 0 to day 12 is the growth date of 0 days (D0), 2 days (D2), 5 days (D5), 7 days (D7), 9 days (D9), and 12 days (D12). was measured, and proliferation and survival were confirmed through morphological analysis of the hair follicles. The following percentage of viability was calculated using the following formula.

viability (%) = (OD _sample /OD _control )ｘ100

As shown in Table 1, Table 2, and attached Figure 1, the control group was 1369 μm at 5 days (D5), 1725 μm at 7 days (D7), 1996 μm at 9 days (D9), and at 12 days (D12). It grew to 2290 μm.

In comparison, in the group treated with sodium metaarsenite at a concentration of 0.03 μg/ml, 1542 μm (113% (viability%)) at 5 days (D5), and 1981 μm (115% (115%) at 7 days (D7) viability%)), 9 days (D9) to 2369 μm (119% (viability%)), and 12 days (D12) to 2890 μm (126% (viability%)) to confirm significant growth compared to the control group. .

In addition, in the group treated with sodium metaarsenite at 0.3 μg/ml, at 5 days (D5) 1539 μm (112% (viability%)), at 7 days (D7) at 1972 μm (114% (viability%)) ), 2345 μm (117% (viability%)) at 9 days (D9), and 2793 μm (122% (viability%)) at 12 days (D12), confirming significant growth compared to the control group.

When sodium metaarsenite was compared with 0.03㎍/ml and 0.3㎍/ml, it showed an excellent effect at 0.03㎍/ml, although it was found that it was not necessarily a good effect at a high dose.

< Example 2>

Preparation of animal models

As an animal test model to verify the hair growth effect of sodium metaarceanite, 10 C57BL/6J rats (Charles River Corp Inc, Barcelona, Spain) weighing 20-25 g at 12 weeks of age were used. After the rats were anesthetized with isoflurane, the back of the rats was pinched with a clipper and hairs were removed. The skin was disinfected with a povidone-iodine solution and then wiped with 60% alcohol.

hair growth effect

Sodium metaarsenite used in the test (CAS Number: 7784-45-5, Batch n° SLBW7984, Ref. S7400 Sigma, Purity: 100%, AD180303-1(R00838) was purchased from Sigma in powder form and used. , Minoxidil was used by purchasing a 3.0 W/V% minoxidil solution produced by Dongsung Pharmaceutical in Korea.

After dissolving sodium metaarsenite in water for injection to be 3.0 W/V%, 100 μl was injected subcutaneously once a day using a needleless syringe. As a negative control, mice without any treatment after hair removal were used, and as a positive control, 300 μl of 3.0 W/V% minoxidil solution was applied once a day.

After breeding for 3 weeks under the same conditions as described above, the results are shown in FIG. 2, and as a result, the hair growth effect is excellent in the back of the rats injected with sodium metaarsenite compared to the back of the rats coated with minoxidil. It was confirmed, and the effect of uniform and dense hair growth was confirmed in mice injected with sodium metaarsenite according to the present invention.

It was confirmed that the composition for injection according to the present invention obtained excellent effects in experiments using human hair follicle cells and experiments using animal models to prevent hair loss and promote hair growth.

Claims (3)

An injection composition for preventing hair loss and promoting hair growth, comprising meta arsenite salt as an active ingredient.
The composition for injection for preventing hair loss and promoting hair growth according to claim 1, wherein the metaarsenite salt is an alkali metal salt or an alkaline earth metal salt.
The composition for injection for preventing hair loss and promoting hair growth according to claim 2, wherein the alkali metal salt is a potassium salt or a sodium salt.

Images